Peterlin P, Gaschet J, Turlure P, Gourin M-P, Dumas P-Y, Thepot S, Berceanu A, Park S, Hospital M-A, Cluzeau T, Torregrosa-Diaz J-M, Drevon L, Sapena R, Chermat F, Ades L, Dimicoli-Salazar S, Jullien M, Fenaux P, Chevallier. P. FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies. haematol [Internet]. 2025Apr.1 [cited 2025Dec.5];110(4):980-4. Available from: https://haematologica.org/article/view/11836